share_log

Sera Prognostics | 8-K: SERA PROGNOSTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS

Sera Prognostics | 8-K: SERA PROGNOSTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS

Sera Prognostics | 8-K:SERA 预测报告了 2024 年第三季度财务业绩
美股SEC公告 ·  2024/11/07 05:15

Moomoo AI 已提取核心信息

Sera Prognostics reported Q3 2024 revenue of $29,000, down from $42,000 in Q3 2023. Operating expenses increased 8% to $8.9 million, with net loss widening to $7.9 million from $7.2 million YoY. R&D expenses remained stable at $3.5 million, while SG&A expenses rose to $5.4 million from $4.6 million.The company made significant progress in commercializing its PreTRM test, including launching a direct-to-consumer testing option with home sample collection in October 2024. Sera also initiated a nationwide awareness campaign featuring TV programs with Dennis Quaid and Meg Ryan, reaching over 84 million homes. The data analysis for the full PRIME study is underway, with publication expected in early 2025.Strategic improvements include transitioning to ambient whole blood collection, which has reduced costs and increased lab capacity. The company has strengthened its commercial team with key hires in sales and marketing, positioning itself for anticipated business growth following the publication of PRIME study results.
Sera Prognostics reported Q3 2024 revenue of $29,000, down from $42,000 in Q3 2023. Operating expenses increased 8% to $8.9 million, with net loss widening to $7.9 million from $7.2 million YoY. R&D expenses remained stable at $3.5 million, while SG&A expenses rose to $5.4 million from $4.6 million.The company made significant progress in commercializing its PreTRM test, including launching a direct-to-consumer testing option with home sample collection in October 2024. Sera also initiated a nationwide awareness campaign featuring TV programs with Dennis Quaid and Meg Ryan, reaching over 84 million homes. The data analysis for the full PRIME study is underway, with publication expected in early 2025.Strategic improvements include transitioning to ambient whole blood collection, which has reduced costs and increased lab capacity. The company has strengthened its commercial team with key hires in sales and marketing, positioning itself for anticipated business growth following the publication of PRIME study results.
Sera Prognostics报告2024年第三季度营业收入为29,000美元,较2023年第三季度的42,000美元下降。营业费用增长8%,达890万,净亏损同比扩大至790万,较720万有所增加。研发费用保持稳定,为350万,而销售、一般和行政费用从460万上升至540万。公司在商业化其PreTRm测试方面取得了重大进展,包括在2024年10月推出家庭样本收集的直接面向消费者的测试选项。Sera还启动了一项全国范围的宣传活动,通过电视节目与Dennis Quaid和Meg Ryan合作,覆盖超过8400万户家庭。全PRIME研究的数据分析正在进行中,预计将在2025年初发表。战略性改善包括转向常温全血采集,这降低了成本并增加了实验室容量。公司在销售和市场营销方面通过关键人才的招聘来加强其商业团队,为预计在PRIME研究结果公布后实现业务增长做好准备。
Sera Prognostics报告2024年第三季度营业收入为29,000美元,较2023年第三季度的42,000美元下降。营业费用增长8%,达890万,净亏损同比扩大至790万,较720万有所增加。研发费用保持稳定,为350万,而销售、一般和行政费用从460万上升至540万。公司在商业化其PreTRm测试方面取得了重大进展,包括在2024年10月推出家庭样本收集的直接面向消费者的测试选项。Sera还启动了一项全国范围的宣传活动,通过电视节目与Dennis Quaid和Meg Ryan合作,覆盖超过8400万户家庭。全PRIME研究的数据分析正在进行中,预计将在2025年初发表。战略性改善包括转向常温全血采集,这降低了成本并增加了实验室容量。公司在销售和市场营销方面通过关键人才的招聘来加强其商业团队,为预计在PRIME研究结果公布后实现业务增长做好准备。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息